2,594 followers
New publication: A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder
New publication: A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder
Randomized, double-blind, active placebo-controlled, dose-response study of Scopolamine for MDD https://t.co/voa9NR1bg2